| Index | Ligand Name | Structure | PDB code | ligand desolvation |
| 1 | 0y7 | Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitors | 4hbm | 91.84 |
| 2 | 2tz | co-crystal structure of MDM2(17-111) in complex with compound 48 | 4occ | 86 |
| 3 | 2sw | co-crystal structure of MDM2 (17-111) in complex with compound 25 | 4oas | 83.93 |
| 4 | hu8 | HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes | 6q9o | 83.19 |
| 5 | 6ss | Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 6g | 5lay | 82.05 |
| 6 | h28 | Crystal structure of MDM2 in complex with compound 13. | 6i3s | 80.65 |
| 7 | 2tw | Co-crystal structure of MDM2 with Inhibitor Compound 4 | 4oba | 78.8 |
| 8 | 7hc | MDM2 in complex with SAR405838 | 5trf | 78.4 |
| 9 | diz | Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor | 1t4e | 77.55 |
| 10 | 6sk | Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) in complex with compound 6b | 5lav | 76.09 |
| 11 | y30 | Structure of a novel submicromolar MDM2 inhibitor | 4mdn | 76.05 |
| 12 | 35s | co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-(6-CYCLOPROPYLPYRIDIN-2-YL)PROPYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID | 4qo4 | 75.47 |
| 13 | mi6 | Structure of human MDM2 protein in complex with Mi-63-analog | 3lbl | 75.46 |
| 14 | 9qw | HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A | 5oc8 | 75.32 |
| 15 | 4th | Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2 | 4zyi | 75.24 |
| 16 | 1my | Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2S)-1-hydroxybutan-2-yl]-3-oxomorpholin-2-yl}acetic acid | 4jwr | 74.3 |
| 17 | 0r2 | crystal structure of MDM2 (17-111) in complex with compound 23 | 4ere | 73.5 |
| 18 | tj2 | Structure of a novel submicromolar MDM2 inhibitor | 3tj2 | 72.91 |
| 19 | 1mt | Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide | 4jvr | 72.59 |
| 20 | 1mq | Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-yl]pent-3-enoic acid | 4jve | 72.48 |
| 21 | yin | crystal structure of MDM2 with chromenotriazolopyrimidine 1 | 3jzk | 71.93 |
| 22 | 2u7 | Co-Crystal Structure of MDM2 with Inhibitor Compound 49 | 4ogv | 69.82 |
| 23 | 1mn | Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one | 4jv7 | 67.31 |
| 24 | 1mo | Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmorpholin-3-one | 4jv9 | 67.3 |
| 25 | 6zt | Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument | 5ln2 | 65.47 |